Skip to main content
Clinical Trials/CTRI/2024/05/067087
CTRI/2024/05/067087
Not yet recruiting
未知

DETERMINATION OF THE RISK PREDICTION OF CARDIOVASCULAR DISEASE AS PER PRAKRITI AMONG PATIENTS OF DIABETES MELLITUS type-2

Chaudhary Brahm Prakash ayurved Charak Sansthan0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Not specified
Sponsor
Chaudhary Brahm Prakash ayurved Charak Sansthan
Status
Not yet recruiting
Last Updated
last year

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
last year
Study Type
Observational

Investigators

Sponsor
Chaudhary Brahm Prakash ayurved Charak Sansthan

Eligibility Criteria

Inclusion Criteria

  • 1 Individuals of both sexes with or without associated risk factors.
  • 2 Individuals willing to participate in this study and has given his consent.
  • 3 Individuals having no history of any apparent disease in last one month.

Exclusion Criteria

  • No past history of cardiovascular events namely Coronary heart disease Stroke etc at the time of enrolment or no evidence of past cardiovascular event and other Individuals with known risk factors on evaluation shown evidence of cardiovascular complications

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Cardiovascular (CV) risk prediction and CV biomarkers in renal transplant recipients treated with belatacept compared to calcineurin inhibitors (CNI)Open randomized 12 month study
EUCTR2013-001178-20-SEppsala University Hospital, MHT, Department of Nephrology105
Active, not recruiting
Phase 1
Cardiovascular (CV) risk prediction and CV biomarkers in renal transplant recipients treated with belatacept compared to calcineurin inhibitors (CNI)Open randomized 12 month studyProphylaxis of graft rejection in adults who have received a renal transplantMedDRA version: 20.0Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 100000022818Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2013-001178-20-DKppsala University Hospital, MHT, Department of Nephrology110
Active, not recruiting
Phase 1
Does conversion to Nulojix reduce the risk of cardiovascular disease in kidney transplant recipients?Prophylaxis of graft rejection in adults who have received a renal transplantMedDRA version: 17.1Level: LLTClassification code 10050436Term: Prophylaxis against renal transplant rejectionSystem Organ Class: 100000004865Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
EUCTR2013-001178-20-NLppsale University Hospital, MHT, Department of Nephrology105
Completed
Phase 4
Cardiovascular (CV) risk prediction and CV biomarkers in renal transplant recipients treated with belatacept compared to calcineurin inhibitors (CNI).;Open randomized 12 month study.cardiovascular risk during prophylaxis of graft rejection in renal transplant recipientscardiovascular risk while preventing rejection of kidney transplant1003843010057166
NL-OMON45007niversity Hospital Uppsala50
Completed
Not Applicable
Risk factor profiling for future arterial cardiovascular events in patients wih unprovoked pulmonary embolismpulmonary embolismvenous embolism1001108210014523
NL-OMON34542eids Universitair Medisch Centrum250